CONGRESS PRESENTATIONS
EACS 2023
October 18-21, 2023
Warsaw, Poland
-
Dolutegravir-based Regimens
Noe S, et al.
3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-Treated People Living with HIV-1 (PLHIV) in Germany: Real-world Data From the German URBAN Cohort
Letang E, et al.
Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People with HIV-1 (PWH) Aged > 50 Years
Letang E, et al.
Real-world effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naïve People with HIV-1 (PWH) and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review
Patel P, et al.
No significant difference in incident hypertension observed by gender, race, baseline BMI or other key subgroups through week 96 among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials
Philibert P, et al.
CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine Fixed Dose Combination (FDC) in treatment-naïve adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results.
-
Cabotegravir Treatment
De los Santos Gil I, et al.
SOLAR 12-month European results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF
Jonsson-Oldenbuettel C, et al.
Efficacy, safety, and implementation outcomes of cabotegravir + rilpivirine long-acting by country in the cabotegravir and rilpivirine implementation study in European locations (CARISEL)
Ghosn J, et al.
Cabotegravir + rilpivirine long-acting efficacy and safety outcomes by sex at birth, age, and race: a subgroup analysis of the CARISEL study
-
Cabotegravir Prevention
-
Fostemsavir
Wonderlich ER, et al.
Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial
Llibre JM, et al.
Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHTE Study
Castagna A, et al.
Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240
-
Pipeline
Leone P, et al.
Safety and Tolerability of VH3810109 (N6LS) Among Antiretroviral Therapy–Naive Adults Living With HIV-1: Results From the Monotherapy Phase of the Phase IIa BANNER Study
Joshi SR, et al.
Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 (GSK’254) as Part of a 2-Drug Regimen (2DR) in Treatment-Naive Adults: 24-Week Results from the Phase IIb DYNAMIC Study
Joshi SR, et al.
Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Randomized, Dose-Range Finding DOMINO Study
Edwards AY, et al.
Utilizing Population Modeling Approaches to Evaluate the Pharmacokinetics and Virological Activity of VH3810109 (N6LS) in the Phase IIa BANNER Study
-
Above Brand
O'Brien P, et al.
Drivers of satisfaction and quality of life of people living with HIV within Europe: Findings from a real-world survey of people living with HIV
Moskwa M, et al.
Patients' fears and expectations related to HIV infection and its treatment in Poland. A Positive Perspective 2 substudy
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.